Latest news with #LeonidTimashev
Business Insider
13-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and GH Research (GHRS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and GH Research (GHRS – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. COMPASS Pathways (CMPS) In a report issued on May 8, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $15.00. The company's shares closed last Monday at $3.91, close to its 52-week low of $2.88. According to Timashev is a 2-star analyst with an average return of -0.5% and a 31.6% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Axsome Therapeutics. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $18.75, representing a 368.8% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $23.00 price target. GH Research (GHRS) RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on May 8 and set a price target of $32.00. The company's shares closed last Monday at $10.16. According to Abrahams ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.0% and a 40.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. Currently, the analyst consensus on GH Research is a Strong Buy with an average price target of $31.43, representing a 199.9% upside. In a report issued on May 9, Guggenheim also maintained a Buy rating on the stock with a $29.00 price target.
Yahoo
02-04-2025
- Business
- Yahoo
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical trial. The drug accomplished its main goal, but side effects reported by some patients raised concerns. Shares of Cytokinetics, one of Edgewise's competitors, surged in Therapeutics (EWTX) shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its latest clinical trial. The company released the results of a Phase 2 trial for EDG-7500, a drug to treat Hypertrophic Cardiomyopathy (HCM), a condition that involves thickened heart muscles, which can make it more difficult for the heart to pump blood effectively. Edgewise said the drug largely accomplished its goal of reducing left ventricular outflow tract gradient (LVOT-G)--a metric that measures how difficult it is for the heart to pump blood--"without meaningful changes in left ventricular ejection fraction (LVEF)." However, the drug's side effects have overshadowed the positive results. The most common side effects were dizziness and an infection in the upper respiratory tract, along with atrial fibrillation (AF), also known as an irregular heartbeat. However, "two participants experienced serious adverse events of AF requiring cardioversion," or treatment to get a heart back to a normal rhythm. The company said that the rate of patients who experienced AF was within the range of similar studies with other drugs. According to Investor's Business Daily, RBC Capital Markets analyst Leonid Timashev wrote in a note, "The fact that two were serious is a complexity that could prompt the FDA to review this closely." Shares of Cytokinetics (CYTK), which is working on a competing drug, jumped 10% on the concerning results for Edgewise. Shares of Edgewise were down 21%. Read the original article on Investopedia Sign in to access your portfolio
Reuters
01-04-2025
- Health
- Reuters
Axsome to narrow focus of depression drug trial after limited success in initial run
April 1 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial run of the trial showed improvement only in a small subgroup of patients. The drug, solriamfetol, did not show statistically significant improvement in the overall group of patients. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. However, it helped reduce symptoms in some patients with major depressive disorder who also suffered from excessive daytime sleepiness (EDS), a common symptom of MDD. "The study missing in the overall MDD population limits the market opportunity significantly, and is disappointing given the company's expertise in the space," RBC Capital Markets analyst Leonid Timashev said in a client note. Axsome said it plans to start a larger late-stage study of the drug in MDD patients with EDS this year. The initial late-stage study that served as a proof of concept for the larger trial had enrolled 346 participants with MDD, of which 51 patients had severe EDS, the company said. The drug was well-tolerated in the study with no new safety concerns, Axsome said. Each year, around 21 million adults in the U.S. are affected by MDD, according to the company. Solriamfetol has already been approved in the U.S. to improve wakefulness in adults with excessive sleepiness from sleep disorders, narcolepsy and sleep apnea, and is sold under the brand Sunosi.
